Ashley & Martin
An Australian hair-loss treatment provider offering medically supervised treatment programs, products, and prescription medicines.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Ashley & Martin is an Australian hair-loss treatment provider founded in 1994 and headquartered in West Perth, Western Australia. The company operates clinics in Australia, New Zealand, and Singapore, with the referenced Wikipedia account describing a network of 21 branches. Its services are directed primarily at people experiencing genetic or pattern hair loss and combine consultation, medical advice, topical treatments, prescription medicines, and other products intended to slow hair loss or support hair regrowth. The company presents its programs as structured treatment plans rather than as a single over-the-counter product. A prominent offering is the RealGROWTH Program, described as a medical treatment intended to help halt genetic hair loss and assist regrowth. Treatment plans may include topical preparations, prescription medicines such as topical finasteride, and products including minoxidil, saw palmetto preparations, specialized shampoos, and laser-cap devices. The precise composition of an individual plan depends on medical assessment and the products prescribed or supplied by the clinic. The business also owns the World Hair Systems group, linking its clinical hair-loss activities with a broader hair-restoration and hair-replacement business. Ashley & Martin has operated in a commercially sensitive category in which treatment outcomes, pricing, contract terms, and advertising claims can materially affect consumers. Its business practices have therefore attracted regulatory and judicial scrutiny. In Australia, the Australian Competition and Consumer Commission challenged contract terms used between 2014 and 2017, alleging that customers could become liable for the full program price before attending an initial medical consultation and had limited rights to withdraw. The Federal Court found for the ACCC. The company subsequently changed its contracts to provide a seven-day cooling-off period, monthly payment options, and a money-back guarantee in specified circumstances. In 2019, the company was ordered to refund qualifying customers who had entered programs before receiving medical advice and later sought cancellation. Ashley & Martin also faced proceedings in New Zealand over claims that its treatments had a 98 percent success rate. In 2022, the New Zealand Commerce Commission announced that the company admitted ten charges involving unsubstantiated representations made between November 2016 and May 2021. The Auckland District Court imposed a fine of NZ$367,500 and ordered payment of court costs. The company stopped using the disputed statistic in its marketing materials. In 2022, Ashley & Martin separately commenced Federal Court proceedings against the men's-health company Pilot, operated by Eucalyptus Health, concerning allegedly misleading online advertising. The reported proceedings sought remedies under Australian consumer law, including declarations, injunctions, compensation, and corrective notices, although an interim application to require removal of the advertising was withdrawn shortly after Pilot appointed legal representation. In 2023, the company also sought relief in the Supreme Court in relation to reporting obligations raised by the Australian Securities and Investments Commission. The court excused the relevant group from filing publicly available director and financial reports for the 2018–19 financial year after accepting that confusion surrounding the statutory definition of large private companies had contributed to the issue. The available reference material identifies Richard Bond as CEO, Dr Mario Terri as medical director and hair-restoration surgeon, and Phillip Raffan as chief executive. Detailed current ownership, revenue, profitability, clinic-by-clinic operations, and the present status of the company's leadership are not established in the supplied sources.
History
Ashley & Martin was founded in 1994 as a provider of hair-loss treatment services. It developed a clinic-based model focused on genetic and pattern hair loss, combining consultations and medical advice with topical preparations, prescription medicines, and other products intended to slow hair loss or support regrowth. The company is based in West Perth and has operated across Australia, New Zealand, and Singapore. The available reference material describes 21 branches and identifies the company as an owner of the World Hair Systems group. Over time, Ashley & Martin positioned its services as individualized treatment programs rather than as a single standardized remedy. Its RealGROWTH Program became a named offering for people seeking to halt genetic hair loss and encourage regrowth. Depending on the medical assessment and selected plan, customers could receive products such as minoxidil, topical finasteride, saw palmetto preparations, shampoos, lotions, and laser-cap devices. The business therefore combines clinical consultation, treatment recommendations, product supply, and hair-restoration expertise. The company's later history includes significant regulatory and legal scrutiny. In 2017, the Australian Competition and Consumer Commission commenced Federal Court proceedings concerning contracts used from 2014 to 2017. The ACCC alleged that customers could be committed to paying the entire program price before their first consultation with a doctor and that cancellation after the initial acceptance period could result in liability for the full fee. The court ruled in the ACCC's favour. Ashley & Martin changed its contract structure to add a seven-day opt-out period, monthly instalment options, and a money-back guarantee in specified circumstances. In 2019, qualifying customers who had joined before receiving medical advice and then sought to cancel were made eligible for refunds. The Australian proceedings also brought attention to the pricing of products used in the treatment plans. The Federal Court expressed concern about the difference between some reported acquisition costs and the prices charged to patients, including shampoo, minoxidil, saw palmetto, and a laser-cap device. These figures are treated here as litigation-related observations rather than as a complete description of the company's pricing model. In New Zealand, the Commerce Commission prosecuted Ashley & Martin under the Fair Trading Act over claims that its programs had a 98 percent success rate. The claims were used between November 2016 and May 2021 and were said to rely on an outdated trial and survey. In 2022, the company admitted ten charges, and the Auckland District Court imposed a NZ$367,500 fine plus NZ$1,500 in court costs. The disputed statistic was subsequently removed from the company's marketing. Ashley & Martin also became involved in a separate advertising dispute with Pilot, a men's-health business operated by Eucalyptus Health. In 2022, it sued in the Federal Court over online representations published in September and October, seeking compensation, injunctions, declarations, and corrective advertising. An interim application seeking removal of the alleged advertising was withdrawn after Pilot appointed legal counsel. In 2023, Ashley & Martin sought relief from reporting obligations after ASIC requested company reports. The court accepted that uncertainty surrounding changes to the definition of a large private company had caused confusion and excused the relevant group from filing publicly available reports for 2018–19. The supplied material names Richard Bond as CEO, Dr Mario Terri as medical director and hair-restoration surgeon, and Phillip Raffan as chief executive. It does not establish the company's current ownership, revenue, profitability, detailed corporate structure, or whether all reported executives remain in their stated roles.
- 2023
Court relief concerning ASIC reports
[1]The company obtained relief from filing certain publicly available reports for the 2018–19 financial year.
- 2022
New Zealand success-rate case concluded
[1]The company admitted ten charges over unsubstantiated 98 percent success-rate representations and received a NZ$367,500 fine.
- 2022
Proceedings commenced against Pilot
[1]Ashley & Martin brought Federal Court proceedings concerning allegedly misleading online advertising by Pilot.
- 2019
Refunds ordered for qualifying customers
[1]Following the ACCC litigation, qualifying customers who had entered treatment before medical advice and later sought cancellation were ordered to receive refunds.
- 2017
ACCC commenced contract proceedings
[1]The ACCC challenged the company's treatment-program contracts and cancellation terms in the Federal Court.
- 1994
Company founded
[1]Ashley & Martin was founded as a hair-loss treatment provider in Australia.
Products and positioning
A clinic-based, medically oriented hair-loss treatment provider offering personalized programs that combine consultation, prescription or topical treatments, and supportive hair-regrowth products.
Medical hair-loss treatment program
RealGROWTH Program
RealGROWTH is a named Ashley & Martin treatment program aimed at people experiencing genetic hair loss. It is described as a medically oriented plan intended to help slow or halt further loss and assist hair regrowth. The program may combine consultation, medical advice, topical preparations, prescription medicines, and supportive devices or products, with the exact treatment determined for the individual.
Prescription hair-loss medicine
Topical finasteride
Topical finasteride is among the medicines Ashley & Martin has been reported to prescribe as part of hair-loss treatment plans. It is supplied within a medical-treatment context rather than presented solely as a general retail cosmetic product.
Hair-loss medicine
Minoxidil
Minoxidil is one of the medicines reported as being supplied or prescribed in Ashley & Martin treatment programs. Its inclusion reflects the company's use of established topical or medication-based approaches within broader individualized treatment plans.
Light-based hair-treatment device
Laser cap
The company's treatment offerings have included a laser-cap device intended to shine light onto the scalp. The device was discussed in the Australian Federal Court proceedings concerning the costs charged to patients and the products used in treatment programs.
Controversies
2022
Unsubstantiated treatment success-rate claims
The New Zealand Commerce Commission alleged that Ashley & Martin made unsubstantiated representations that its treatment had a 98 percent success rate. The company admitted ten Fair Trading Act charges relating to claims used between November 2016 and May 2021. The Auckland District Court imposed a NZ$367,500 fine and NZ$1,500 in court costs.
Brand decisions
2022
Removed the disputed 98 percent marketing statisticOtherBackground
The New Zealand Commerce Commission challenged the use of a 98 percent success-rate claim based on an outdated trial and survey.
Action taken
Ashley & Martin admitted ten charges and no longer used the statistic in its marketing materials.
Aftermath
The Auckland District Court imposed a NZ$367,500 fine and ordered NZ$1,500 in court costs.
Court-imposed fine. NZ$367,500 (2022)
2017
Defended treatment-program contract practicesOtherBackground
The ACCC alleged that customers could be bound to full payment before an initial medical consultation and had limited cancellation rights under contracts used between 2014 and 2017.
Action taken
Ashley & Martin contested the ACCC proceedings, which ultimately resulted in a ruling for the regulator.
Aftermath
The company revised its contracts to include a seven-day opt-out period, monthly instalments, and a specified money-back guarantee. Qualifying customers were later entitled to refunds.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/ashley-and-martin · Editorial policy · How profiles are compiled